Author:
Kowal-Bielecka Otylia,Fransen Jaap,Avouac Jerome,Becker Mike,Kulak Agnieszka,Allanore Yannick,Distler Oliver,Clements Philip,Cutolo Maurizio,Czirjak Laszlo,Damjanov Nemanja,del Galdo Francesco,Denton Christopher P,Distler Jörg H W,Foeldvari Ivan,Figelstone Kim,Frerix Marc,Furst Daniel E,Guiducci Serena,Hunzelmann Nicolas,Khanna Dinesh,Matucci-Cerinic Marco,Herrick Ariane L,van den Hoogen Frank,van Laar Jacob M,Riemekasten Gabriela,Silver Richard,Smith Vanessa,Sulli Alberto,Tarner Ingo,Tyndall Alan,Welling Joep,Wigley Frederic,Valentini Gabriele,Walker Ulrich A,Zulian Francesco,Müller-Ladner Ulf
Abstract
The aim was to update the 2009 European League against Rheumatism (EULAR) recommendations for the treatment of systemic sclerosis (SSc), with attention to new therapeutic questions. Update of the previous treatment recommendations was performed according to EULAR standard operating procedures. The task force consisted of 32 SSc clinical experts from Europe and the USA, 2 patients nominated by the pan-European patient association for SSc (Federation of European Scleroderma Associations (FESCA)), a clinical epidemiologist and 2 research fellows. All centres from the EULAR Scleroderma Trials and Research group were invited to submit and select clinical questions concerning SSc treatment using a Delphi approach. Accordingly, 46 clinical questions addressing 26 different interventions were selected for systematic literature review. The new recommendations were based on the available evidence and developed in a consensus meeting with clinical experts and patients. The procedure resulted in 16 recommendations being developed (instead of 14 in 2009) that address treatment of several SSc-related organ complications: Raynaud's phenomenon (RP), digital ulcers (DUs), pulmonary arterial hypertension (PAH), skin and lung disease, scleroderma renal crisis and gastrointestinal involvement. Compared with the 2009 recommendations, the 2016 recommendations include phosphodiesterase type 5 (PDE-5) inhibitors for the treatment of SSc-related RP and DUs, riociguat, new aspects for endothelin receptor antagonists, prostacyclin analogues and PDE-5 inhibitors for SSc-related PAH. New recommendations regarding the use of fluoxetine for SSc-related RP and haematopoietic stem cell transplantation for selected patients with rapidly progressive SSc were also added. In addition, several comments regarding other treatments addressed in clinical questions and suggestions for the SSc research agenda were formulated. These updated data-derived and consensus-derived recommendations will help rheumatologists to manage patients with SSc in an evidence-based way. These recommendations also give directions for future clinical research in SSc.
Subject
General Biochemistry, Genetics and Molecular Biology,Immunology,Immunology and Allergy,Rheumatology